Cytokine Release Syndrome
On this page
Direct answer
Fever with hypotension and hypoxia appearing three to seven days after CAR T-cell infusion — or within days of blinatumomab, and occasionally other monoclonals — is cytokine release syndrome: massive interleukin-6, TNF-alpha and interferon-gamma release from activated immune effector cells, producing capillary leak, vasodilatory shock and end-organ dysfunction that mimics sepsis. Grading by the ASTCT criteria runs from grade 1 (fever alone), through grade 2 (fluid-responsive hypotension, low-flow oxygen requirement), to grade 3 (vasopressors, high-flow oxygen) and grade 4 (life-threatening instability). Tocilizumab, the anti-interleukin-6-receptor antibody, is the licensed antidote, given early for grade 2 and above with corticosteroids added for grade 3-4 and whenever neurotoxicity appears; cultures are drawn in parallel because infection remains the great imitator.
What you must remember
- Triggers and timing: CAR T cells — fever typically day 3-7 after infusion; blinatumomab and high-grade lymphocyte-depleting antibodies — within the first days, mitigated by step-up dosing.
- Mediators: IL-6 drives fever and vascular leak — hence tocilizumab; TNF-alpha and interferon-gamma amplify the storm; ferritin, CRP and falling albumin track severity.
- ASTCT grading: grade 1 fever with no hypotension or hypoxia; grade 2 hypotension responding to fluids and hypoxia needing low-flow oxygen; grade 3 vasopressor-requiring hypotension and/or high-flow oxygen; grade 4 life-threatening cardiopulmonary compromise.
- Tocilizumab dosing: 8 mg/kg intravenously (many protocols allow repeat doses at eight-hourly intervals), licensed for CAR T-cell-associated CRS after demonstration in pivotal trials.
- Steroids: second-line in pure CRS to avoid blunting the anti-tumour effect, but first-line when neurotoxicity coexists or grade 4 physiology threatens.
- ICANS: CAR T-cell-related encephalopathy — confusion, aphasia, tremor, seizures, cerebral oedema — scored by the ICE tool, worsened by severe CRS, treated with dexamethasone or methylprednisolone.
- Differential discipline: sepsis, tumour lysis syndrome and haemophagocytic lymphohistiocytosis overlap almost perfectly — cultures, urate, LDH and ferritin adjudicate while treatment proceeds.
Managing a fever on day 4 after CAR T infusion
A 19-year-old with relapsed B-cell acute lymphoblastic leukaemia develops temperature 39.2 degrees on day 4 after CD19-directed CAR T-cell therapy. First act: vitals establish the grade — blood pressure holds with a litre of crystalloid, oxygen saturation is 93 percent on nasal specs at 2 litres, so this is grade 2. Second act: infection screen in parallel — blood, urine and line cultures, chest radiograph — but antimicrobial treatment waits on nothing; febrile neutropenia cover starts because the two diagnoses coexist comfortably. Third act: tocilizumab 8 mg/kg intravenously, with paracetamol and fluid support; antihistamines and steroids pre-empted nothing here. Fourth act: the next 12 hours decide the trajectory — vasopressor requirement upgrades to grade 3 and adds dexamethasone plus intensive care; resolution instead downgrades care. Throughout, hourly neurological observation with the ICE score catches the whispered word-finding difficulty that signals ICANS, treated decisively with steroids rather than observed hopefully.
The reasoning to articulate: why tocilizumab before steroids in isolated CRS — IL-6 blockade controls the syndrome without deleting the engineered T cells, whereas early high-dose steroids can blunt the graft-versus-tumour effect that is the whole point of the therapy.
The Indian perspective
CAR T-cell therapy has crossed from trial to approved use in India, with indigenous CD19 constructs reported and tertiary centres in metros delivering them — which converts CRS from an examination curiosity into district-hospital reality, since patients return home during follow-up and may re-present locally. Practical Indian points: tocilizumab became familiar during COVID-19, so intensivists have handled the drug, but its cost still rationises use; a febrile post-CAR-T patient in a monsoon-season district hospital carries dengue, typhoid and sepsis in the differential alongside CRS, so the ASTCT grade must be applied after infection data, not before; and any centre administering immune effector therapies must stock tocilizumab and write the escalation pathway before the first infusion, not after the first emergency.
Frequently asked questions
Which drug is licensed for CAR T-cell-associated cytokine release syndrome?
Tocilizumab, an interleukin-6 receptor blocker, 8 mg/kg intravenously with repeat dosing permitted — the first-line antidote for grade 2 and above.
When does CRS typically begin after CAR T-cell infusion?
Around day 3-7 for most constructs, earlier with some products and with blinatumomab — timing itself is a diagnostic clue.
What is ICANS and how is it assessed?
Immune effector cell-associated neurotoxicity — confusion, aphasia, seizures, cerebral oedema — graded by the ICE (immune effector cell-associated encephalopathy) score.
What defines ASTCT grade 3 CRS?
Hypotension requiring vasopressors and/or hypoxia needing high-flow oxygen, mandating intensive care and steroid addition.
Why do steroids trail tocilizumab in isolated CRS?
High-dose steroids suppress the engineered T cells and may blunt anti-tumour efficacy, so they are reserved for grade 3-4 disease and neurotoxicity.